Literature DB >> 26227663

The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency (Addison's Disease).

Katharina Schultebraucks1, Katja Wingenfeld, Christian Otte, Marcus Quinkler.   

Abstract

BACKGROUND: Primary adrenal insufficiency (AI) requires hormone replacement therapy with fludrocortisone and hydrocortisone stimulating glucocorticoid (GR) and mineralocorticoid receptors (MR). Evidence from animal and human studies shows that MR function is crucial for cognitive function and mood. Regarding patients with AI, very little is known about the role of MR in cognitive function and mood.
METHODS: A repeated-measures within-subject design was used to determine whether cognitive function and mood are related to MR occupation in patients with AI. Intraindividually, patients were examined twice, with 1 week between testing days: once with fludrocortisone (high MR occupation) and once without fludrocortisone (low MR occupation). All patients kept their stable regimen of hydrocortisone. The assessment of cognitive function included executive function, attention, and verbal, visuospatial and working memory. Additionally, mood and blood pressure were measured.
RESULTS: Verbal memory improved significantly during high MR occupation (after fludrocortisone intake) compared to low MR occupation [without fludrocortisone, t(29) = -2.1, p = 0.046]. There were trend level differences in the Number-Combination test [t(29) = -1.9, p = 0.074] and in the Stroop interference task [t(29) = -1.9, p = 0.068]. No significant differences in visuospatial and working memory were found. Furthermore, the current mood state was better during high MR occupation compared to low MR occupation [t(29) = -2.4, p = 0.023] as was diastolic blood pressure [F(2, 29) = 3.6, p = 0.07].
CONCLUSIONS: Cognitive function and mood in patients with AI depend in part on MR occupation. Because the medium effect size indicates a potential clinical significance, further studies should systematically examine which dosages of fludrocortisone are associated with optimal cognitive function and mood in AI patients.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26227663     DOI: 10.1159/000438791

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  7 in total

Review 1.  Adrenal insufficiency.

Authors:  Stefanie Hahner; Richard J Ross; Wiebke Arlt; Irina Bancos; Stephanie Burger-Stritt; David J Torpy; Eystein S Husebye; Marcus Quinkler
Journal:  Nat Rev Dis Primers       Date:  2021-03-11       Impact factor: 52.329

2.  Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency.

Authors:  F Ceccato; M Torchio; I Tizianel; M Peleg Falb; M Barbot; C Sabbadin; C Betterle; C Scaroni
Journal:  J Endocrinol Invest       Date:  2022-08-10       Impact factor: 5.467

Review 3.  Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults.

Authors:  C Betterle; F Presotto; J Furmaniak
Journal:  J Endocrinol Invest       Date:  2019-07-18       Impact factor: 5.467

4.  Plasma renin levels are associated with cardiac function in primary adrenal insufficiency.

Authors:  Peter Wolf; Hannes Beiglböck; Paul Fellinger; Lorenz Pfleger; Stefan Aschauer; Alois Gessl; Rodrig Marculescu; Siegfried Trattnig; Alexandra Kautzky-Willer; Anton Luger; Yvonne Winhofer; Martin Krššák; Michael Krebs
Journal:  Endocrine       Date:  2019-06-08       Impact factor: 3.633

5.  Sex-Specific Limitations in Physical Health in Primary Adrenal Insufficiency.

Authors:  Nora Møller Didriksen; Åse Bjorvatn Sævik; Linn Solveig Sortland; Marianne Øksnes; Eystein Sverre Husebye
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-18       Impact factor: 5.555

6.  Editorial: Primary Adrenal Insufficiency - Quality of Life and Long-Term Outcome With Current Treatment Strategies.

Authors:  Daniela Esposito; Alberto Falorni; Gudmundur Johannsson
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 5.555

7.  Brain mineralocorticoid receptor in health and disease: From molecular signalling to cognitive and emotional function.

Authors:  Susana N Paul; Katja Wingenfeld; Christian Otte; Onno C Meijer
Journal:  Br J Pharmacol       Date:  2022-04-07       Impact factor: 9.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.